All In Biotech

Free tool

FAERS Monitor: Daptomycin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210282 or its brand name (Daptomycin, Daptomycin). Reports on generic versions are filed under their own applications.

Reports

9,502

Serious

8,805

93% of reports

Hospitalization

5,435

Death reported

1,286

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective768
  • off label use703
  • acute kidney injury628
  • eosinophilic pneumonia487
  • pyrexia481
  • rhabdomyolysis389
  • eosinophilia387
  • drug reaction with eosinophilia and systemic symptoms344
  • blood creatine phosphokinase increased329
  • product use in unapproved indication321
  • neutropenia302
  • thrombocytopenia288
  • rash282
  • interstitial lung disease275
  • pneumonitis265

Reports by year received

View as table
YearReports
200410
200521
200622
200723
200831
200978
201067
201187
2012121
2013117
2014128
2015319
2016237
2017307
2018595
2019491
2020665
2021836
2022899
20231,100
20241,107
20251,182
20261,059

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,657 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
eosinophilic pneumoniaSignal487404.4368.0165,403
eosinophiliaSignal38750.045.318,129
drug reaction with eosinophilia and systemic symptomsSignal34430.027.09,491
blood creatine phosphokinase increasedSignal32925.623.07,669
pneumonitisSignal26521.719.35,179
rhabdomyolysisSignal38920.818.97,272
interstitial lung diseaseSignal27512.611.22,926
acute kidney injurySignal6289.18.54,545
thrombocytopeniaSignal2885.75.11,118
neutropeniaSignal3024.94.4945
pyrexiaSignal4813.12.8684
product use in unapproved indicationSignal3212.92.6393
off label use7031.81.7249
rash2821.41.337
drug ineffective7681.31.253

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.